Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Collaboration will focus on topical anti-HPV treatment
March 24th, 2005
Collaboration between pharmaceutical companies will focus on a topical treatment of human papillomavirus. 3M Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have entered into an exclusive codevelopment and joint marketing agreement to collaborate on a potential topical treatment for human papillomavirus (HPV) infection and cervical dysplasia. The compound is currently in early stage (Phase I) clinical testing. It is part of the family of immune response modifier (IRM) molecules developed by 3M Pharmaceuticals. IRMs stimulate the human body's immune system to fight virus-infected cells and tumor cells. HPV is associated with...
Source: Women's Health Weekly (2005-03-24)
|
